Q32 Bio Advances Bempikibart After Positive Phase 2 Data

Company: Q32 Bio Event type: Phase 2 clinical data and development prioritization Modality: Monoclonal antibody / immune pathway modulation Asset: Bempikibart Target: IL-7Rα, with blockade of IL-7 and TSLP signaling Disease area: Alopecia areataInsilens signal strength: 3 / 5 Summary Q32 Bio reported positive 36-week…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Zynlonta Safety Concerns Raise Regulatory Risk
Fortress Biotech, $205M Priority Review Voucher Sale
CellCentric – $220M Financing for Inobrodib
Long-Acting Anti-Influenza Monoclonal Antibody Platform Targets Immunocompromised Patients